Loading
Life sciences · Journal article
Discover Oncology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Homeobox ( HOX ) genes encode evolutionarily conserved transcription factors that govern developmental identity and differentiation. In breast cancer, HOX dysregulation is bidirectional and context dependent rather than uniformly oncogenic: HOXA2, HOXA5, and HOXC8 show tumor-suppressive or differentiation-associated functions, whereas HOXB7, HOXB9, HOXB13, and HOXC10 are linked to progression or treatment resistance in defined settings. This review critically integrates evidence from human tumors and clinical cohorts with mechanistic findings from cell and animal models. Beyond effects on proliferation, apoptosis, epithelial-mesenchymal transition, invasion, and angiogenesis, HOX networks may influence lineage state, stem-like phenotypes, cellular plasticity, and therapy adaptation. We propose that apparently paradoxical HOX functions can be understood through interactions among PBX/MEIS cofactors, chromatin accessibility, signaling context, and post-translational regulation. Particular attention is given to subtype-associated patterns, the clinically translated HOXB13:IL17BR component of the Breast Cancer Index, and therapy-driven tumor evolution. Direct HOX -targeted strategies-including HOX-PBX inhibitors, RNA-based approaches, epigenetic modulation, and dependency-guided combination strategies-remain preclinical in breast cancer. Major barriers include functional redundancy, delivery and pharmacokinetic limitations, patient selection, and potential on-target/off-tumor effects in normal stem and progenitor compartments. Future longitudinal, single-cell, spatial, epigenomic, and functional-genomic studies should determine which HOX alterations are drivers, biomarkers of cell state, or therapeutically exploitable dependencies.